Plasma Dihydroceramide Species Associate with Waist Circumference in Mexican American Families

Manju Mamtani[1], Peter J. Meikle[2], Hemant Kulkarni[1], Jacquelyn M. Weir[2], Christopher K. Barlow[2], Jeremy B. Jowett[2], Claire Bellis[1], Thomas D. Dyer[1], Laura Almasy[1], Michael C. Mahaney[1], Ravindranath Duggirala[1], Anthony G. Comuzzie[1], John Blangero[1] and Joanne E. Curran[1]

Objective: Waist circumference (WC), the clinical marker of central obesity, is gaining popularity as a screening tool for type 2 diabetes (T2D). While there is epidemiologic evidence favoring the WC-T2D association, its biological substantiation is generally weak. Our objective was to determine the independent association of plasma lipid repertoire with WC.

Methods: Samples and data from the San Antonio Family Heart Study of 1208 Mexican Americans from 42 extended families were used. Association of plasma lipidomic profiles with the cross-sectionally assessed WC was determined. Plasma lipidomic profiling entailed liquid chromatography with mass spectrometry. Statistical analyses included multivariable polygenic regression models and bivariate trait analyses using the SOLAR software.

Results: After adjusting for age and sex interactions, body mass index, homeostasis model of assessment—insulin resistance, total cholesterol, triglycerides, high density lipoproteins and use of lipid lowering drugs, dihydroceramides as a class were associated with WC. Dihydroceramide species 18:0, 20:0, 22:0, and 24:1 were significantly associated and genetically correlated with WC. Two sphingomyelin species (31:1 and 41:1) were also associated with WC.

Conclusions: Plasma dihydroceramide levels independently associate with WC. Thus, high resolution plasma lipidomic studies can provide further credence to the biological underpinnings of the association of WC with T2D.

Introduction

Waist circumference (WC), the established surrogate for central obesity (1-4), is continuing to gain importance as a potential screening method for Type 2 diabetes (T2D) and insulin resistance (IR) (5-7). Evidence for the association of WC with these conditions has been gleaned mostly from epidemiological studies (8-11). Recently some family-based studies have also offered associations compatible with these epidemiological observations (12). Waist circumference is strongly associated with visceral rather than subcutaneous fat (13-16) as well as commonly used clinical indexes of lipemic status like total serum cholesterol, serum triglycerides and serum high-density lipoprotein (HDL) cholesterol (17). On the other hand, reasons (18) for not favoring the use of WC for identification or stratification of T2D risk include (i) WC correlates strongly with body mass index (BMI) (19); (ii) WC cannot distinguish between subcutaneous and visceral fat; (iii) age- and sex-adjusted models do not offer a convincing proof of association between WC and visceral fat; (iv) race, age, and sex can confound the association of WC with

[1] Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, USA. Correspondence: Manju Mamtani (mmamtani@txbiomedgenetics.org) [2] Department of Metabolomics, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 3004, Australia

FIGURE 1 Statistical method used to study the association of a class of lipids with a phenotypic trait. A lipid class is a collection of s lipid species (rectangle on the left). For a given lipid class, three models (M_1, M_2, and M_3 described in a tabular format on the right) were run and log-likelihoods from these three models were used as shown at the bottom to estimate the mean effect, its statistical significance and heterogeneity of within-class associations. For details, refer to text.

T2D; and (v) WC, like BMI, is a highly heritable trait that may capture genetic similarity rather than risk of T2D (18,20,21). It is noteworthy in this regard that direct or associative evidence in favor of WC that is primarily based on the biological underpinnings of T2D/IR pathogenesis is currently weak.

There is now a growing interest in the characterization of the vast repertoire of plasma lipids and their potential contributions to several complex diseases (22-25). Of special interest, plasma lipid species as measured by lipidomic profiling are being increasingly associated with the risk of T2D/IR and have been shown to be better predictors than the lipoprotein fractions that are commonly used in clinical practice (26-28). In this context, we reasoned that associations of key plasma lipid species with WC could lend further biologically meaningful support to the candidature of WC as a crucial link between obesity and T2D/IR. In this regard, whether WC is associated with the enormous variety of plasma lipids is currently unknown. Here we investigated the potential association of a large array of plasma lipid species with WC using rich data from the ongoing San Antonio Family Heart Study (29) in large and extended Mexican American families—a high risk population for both obesity and T2D/IR.

Methods

Study participants
The San Antonio Family Heart Study (SAFHS) is an ongoing effort focusing on 1,431 individuals from 42 large, extended Mexican American families in San Antonio. Details of this collaborative study have been described elsewhere (21,29). Briefly, the SAFHS aims to quantify the relative contributions of genetic and environmental factors to the risk of developing cardiovascular diseases and metabolic syndrome. Extensive phenotypic assessment for a number of traits related to metabolic syndrome has been performed in these

individuals. This project involving the Texas Biomedical Research Institute and the University of Texas Health Science Center at San Antonio was initiated in 1991. Informed consent was obtained from all participants before collection of samples. The Institutional Review Board of the University of Texas Health Sciences Center at San Antonio approved the study. Using this data, we aimed to determine the association of the plasma lipid species with concurrently and cross-sectionally measured WC.

Lipidomic studies
Samples were analyzed in the Metabolomics Laboratory at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. Analytical methods have been detailed elsewhere (30). Briefly, a 10-μL aliquot of plasma was combined with 200 μL $CHCl_3$/MeOH (2:1) and 15μL of internal standard mix and then briefly vortexed. Samples were mixed (rotary mixer, 10 min), sonicated (water bath, 30 min) then allowed to stand (20 min) at room temperature. Samples were centrifuged (16,000g, 10 min) and the supernatant was dried under a stream of nitrogen at 40°C. The extracted lipids were resuspended in 50 μL H_2O saturated BuOH with sonication (10 min), followed by 50μL of 10 mM NH_4COOH in MeOH. Extracts were centrifuged (3,350g, 5 min) and the supernatant transferred into 0.2 mL glass vials with teflon insert caps. Mass spectrometric analysis was performed using 5 μL and 1 μL [for diacylglycerol and triacylgrlycerol (DG and TG) species, respectively] injections of the lipid extracts.

Identification and quantitation of lipid species was performed by liquid chromatography electrospray ionisation-tandem mass spectrometry using an Applied Biosystems 4000 QTRAP. Liquid chromatography was performed on a Zorbax C18, 1.8 μm, 50 $\times$ 2.1 mm^2 column at 300 μL min^{-1} using the following gradient conditions; 0% B to 100% B over 8.0 min, 2.5 min at 100% B, a return to 0% B over 0.5 min then 3.0 min at 0% B prior to the next injection.

TABLE 1 Within-lipid class heterogeneity of association with WC

Lipid class	Class	Lipid species	Nominal within-class heterogeneity	FDR adjusted within-class heterogeneity
Dihydroceramide	dhCer	6	3.92×10^{-2}	0.5489
Ceramide	Cer	6	2.12×10^{-2}	0.3392
Monohexosylceramide	MHC	6	9.49×10^{-2}	0.6090
Dihexosylceramide	DHC	6	1.27×10^{-4}	0.0027
Trihexosylceramide	THC	6	1.24×10^{-1}	0.6090
GM3 ganglioside	GM3	6	7.20×10^{-3}	0.1296
Sphingomyelin	SM	19	9.22×10^{-5}	0.0020
Phosphatidylcholine	PC	45	4.43×10^{-2}	0.5489
Ether-linked phosphatidylcholines	PC(O)	18	4.68×10^{-2}	0.5489
Plasmalogen phosphatidylcholines	PC(P)	8	1.85×10^{-3}	0.0370
Lysophosphatidylcholine	LPC	21	2.31×10^{-3}	0.0439
Ether-linked lysophosphatidylcholines	LPC(O)	6	9.68×10^{-1}	0.9680
Phosphatidylethanolamine	PE	18	4.99×10^{-2}	0.5489
Ether-linked phosphatidylethanolamines	PE(O)	12	1.38×10^{-1}	0.6090
Plasmalogen phosphatidylethanolamines	PE(P)	9	1.82×10^{-1}	0.6090
Lysophosphatidylethanolamine	LPE	6	3.95×10^{-1}	0.7900
Phosphatidylinositol	PI	17	1.20×10^{-1}	0.6090
Phosphatidylserine	PS	7	1.75×10^{-1}	0.6090
Phosphatidylglycerol	PG	4	2.03×10^{-1}	0.6090
Cholesterol ester	CE	26	1.53×10^{-1}	0.6090
Cholesterol	COH	1	-	-
Diacylglycerol	DG	22	7.64×10^{-3}	0.1299
Triaclyglycerol	TG	43	4.86×10^{-2}	0.5489

DGs and TGs were separated using the same solvent system with an isocratic flow (100 μL min^{-1}) of 85% B. Solvent A and B consisted of tetrahydrofuran:methanol:water in the ratios (30:20:50) and (75:20:5), respectively, both containing 10 mM NH$_4$COOH. Precursor ion scans and neutral loss scans were used to identify the lipid species present in human plasma. Quantification of individual lipid species was then performed using scheduled multiple-reaction monitoring (MRM) in positive ion mode (31,32). Lipid concentrations were calculated by relating the peak area of each species to the peak area of the corresponding internal standard. CE species were corrected for response factors determined for each species. Total measured lipids of each class were calculated by summing the individual lipid species.

Statistical analysis

Our analyses were designed with the aim to minimize the number of statistical tests. For this, we conducted the statistical analyses at two levels: lipid classes and lipid species. To assess the association of each lipid class with WC, we used a three-step procedure (Figure 1). First, we ran a polygenic regression model in which we included all the lipid species within a given class as covariates (base model, denoted as M_1 in Figure 1). These regression models included age, age^2, sex, age $\times$ sex interaction and age^2 $\times$ sex interaction, BMI, homeostasis model of assessment—insulin resistance (HOMA-IR), use of lipid lowering drugs, total plasma cholesterol, plasma triglycerides, and plasma high-density (HDL) lipoproteins as additional covariates. Second, we ran a model by constraining the regression

coefficients of all the lipid species within the class to be equal (alternative model, denoted as M_2 in Figure 1) and third, we ran another model by constraining these regression coefficients to be zero (null model, denoted as M_3 in Figure 1). The alternative model provided the regression coefficient for the mean of all lipid species within a class while comparison of the log-likelihoods of the alternative model and the null model gave a test for the significance of this mean regression coefficient. Further, comparison of the log-likelihoods from the base model and the alternative model provided a test for heterogeneity of associations within the given lipid class.

We next examined the association of lipid species with WC. In these analyses, we selected the lipid species that represented one of the following two types of lipid classes: (i) a lipid class showing statistically significant association of the mean of all lipid species within that class and statistically nonsignificant within-class heterogeneity; or (ii) a lipid class showing statistically significant within-class heterogeneity. For this, we ran polygenic models with the given lipid species as the covariate and tested the statistical significance by constraining this regression coefficient to zero and then estimating χ^2 as -2(LL$_{\text{unconstrained model}}$–LL$_{\text{constrained model}}$), where LL represents the log-likelihood.

Next, we conducted bivariate trait analyses in which we used each lipid species in a separate bivariate polygenic model along with WC as the two traits. Using this series of models and variance components methods we estimated the genetic correlation (ρ_g) and the environmental correlation (ρ_e) coefficients as described elsewhere (33). The statistical significance of these correlation coefficients was

tested by constraining the respective parameters to zero and estimating the χ^2 statistics as mentioned above. All genetic analyses were conducted using the sequential oligogenic linkage analysis routines (SOLAR) software (33). Statistical significance was assessed at a global type I error rate of 0.05 and, where appropriate, the false discovery rate (FDR) approach using the method of Benjamini and Hochberg was used to correct for multiple comparisons.

Results

Study subjects

Cross-sectional data on lipidomic profiles and WC was available on 1208 subjects representing 42 extended families. The mean age of the study sample was 37.0 (SD 14.39) years and there were 292 (36.1%) males. Prevalence of IR was 74.6% based on a HOMA-IR cut-off of 2.6 (the commonly used clinical cut-point for IR) and 56.1% using a cut-off of 3.8 (as specifically recommended (34) for Mexican-American populations). The prevalence of T2D and obesity in this sample was 14.8 and 38.3%, respectively.

Association of plasma lipid classes with WC

To optimize the number of statistical tests being performed, we first conducted our analyses at the level of lipid classes. We studied the association of 23 lipid classes listed in Table 1 with WC. In multivariable polygenic regression models including the aforementioned covariates, we found (Figure 2) that the standardized regression coefficient (class-specific regression coefficient divided by its standard error) for the class of dihydroceramides was the only statistically significant (FDR-corrected $P = 0.0003$) class-level regression coefficient. Interestingly, the FDR-corrected heterogeneity around this mean class effect for dihydroceramides was not statistically significant ($P = 0.5489$, Table 1) indicating that the six species constituting this class were likely associated with WC in a homogeneous fashion. No other class of plasma lipids was significantly associated with WC. It is noteworthy in this regard that ceramides have been previously implicated in the pathogenesis of T2D and IR, but we found no significant association of this class with WC (mean class effect = 0.0024, SE = 0.0039, $P = 0.5398$).

Association of lipid species with WC

We next examined the association of lipid species with WC. On the basis of the results shown in Table 1, we selected 60 lipid species belonging to the following five classes: dihydroceramides (six species), dihexocylceramides (6 species), sphingomyelins (19 species), plasmalogen phosphatidylcholines (8 species), and lysophosphatidylcholines (21 species). Consistent with the results at the level of lipid class, we found (Table 2) that four (dhCer 24:1, dhCer 18:0, dhCer 20:0, and dhCer 22:0) of the six dihydroceramide species were statistically significantly associated with WC. In addition, two sphingomyelin species (SM 31:1 and SM 41:1) were also significantly associated with WC. Interestingly however, most of the sphingomyelin species were inversely associated with WC.

Genetic correlations of lipid species with WC

To glean further biologically meaningful support for the clinical utility of WC, we conducted bivariate trait analyses in SOLAR and estimated the genetic and environmental correlations of each


FIGURE 2 Associations of the lipid classes with WC. The strength of the association of each lipid class is shown as z-score (the class-specific regression coefficient divided by its standard error) estimated from polygenic regression models and the statistical significance of this association is indicated by the asterisk on the right.

significantly associated lipid species with WC. We observed (Table 3) that the dihydroceramide 22:0 and dihydroceramide 24:1 species were significantly genetically correlated with WC. In contrast, the dihydroceramide 18:0 and dihydroceramide 20:0 species were significantly environmentally but not genetically correlated with WC. Of note, both the sphingomyelin species were significantly environmentally but not genetically correlated with WC.

Discussion

Our results demonstrate that dihydroceramides as a lipid class are consistently associated with WC in Mexican Americans. Of the six dihydroceramide species investigated in this study, four species showed a strong association with WC and were significantly genetically as well as environmentally correlated with WC. Notably, we have recently found dihydroceramides to be crucial determinants of future risk of T2D also (35). In that study (data not shown), we identified 210 lipid species that correlated with diabetes status (FDR ≤ 0.05); of which 128 also predicted progression to diabetes in non-diabetics followed for ~10 years. The single best predictor of progression to diabetes was dhCer 18:0 which was significantly heritable ($h^2 = 0.247$; $P = 1.6 \times 10^{-9}$) and was markedly increased in diabetics ($P = 2.5 \times 10^{-7}$) compared to non-diabetics. Those

TABLE 2 Multivariable association of plasma dihydroceramide species with WC[a]

Lipid species	β	Nominal p	FDR-p
dhCer 16:0	0.0354	1.19×10^{-2}	4.89×10^{-1}
dhCer 18:0	0.0706	1.82×10^{-5}	$\mathbf{1.06 \times 10^{-3}}$
dhCer 20:0	0.0687	1.42×10^{-5}	$\mathbf{8.38 \times 10^{-4}}$
dhCer 22:0	0.0615	4.84×10^{-4}	$\mathbf{2.66 \times 10^{-2}}$
dhCer 24:0	0.0456	4.98×10^{-3}	2.49×10^{-1}
dhCer 24:1	0.0835	3.51×10^{-7}	$\mathbf{2.11 \times 10^{-5}}$
Cer 16:0	0.0244	1.06×10^{-01}	4.89×10^{-1}
Cer 18:0	0.0310	4.15×10^{-02}	4.89×10^{-1}
Cer 20:0	0.0093	3.07×10^{-01}	4.89×10^{-1}
Cer 22:0	-0.0183	1.77×10^{-01}	4.89×10^{-1}
Cer 24:0	-0.0330	4.95×10^{-02}	4.89×10^{-1}
Cer 24:1	0.0351	3.23×10^{-02}	4.89×10^{-1}
DHC 16:0	0.0007	4.83×10^{-1}	4.89×10^{-1}
DHC 18:0	0.0052	3.67×10^{-1}	4.89×10^{-1}
DHC 20:0	0.0413	1.70×10^{-3}	9.18×10^{-2}
DHC 22:0	0.0096	2.57×10^{-1}	4.89×10^{-1}
DHC 24:1	0.0298	2.50×10^{-2}	4.89×10^{-1}
DHC 24:0	0.0091	2.78×10^{-1}	4.89×10^{-1}
SM 31:1	-0.0652	1.26×10^{-4}	$\mathbf{7.18 \times 10^{-3}}$
SM 32:1	-0.0196	1.58×10^{-1}	4.89×10^{-1}
SM 32:2	-0.0180	2.00×10^{-1}	4.89×10^{-1}
SM 33:1	-0.0496	3.55×10^{-3}	1.81×10^{-1}
SM 34:1	-0.0034	4.29×10^{-1}	4.89×10^{-1}
SM 34:2	0.0141	2.65×10^{-1}	4.89×10^{-1}
SM 34:3	-0.0217	1.18×10^{-1}	4.89×10^{-1}
SM 35:1	-0.0368	1.56×10^{-2}	4.89×10^{-1}
SM 35:2	-0.0433	5.83×10^{-3}	2.86×10^{-1}
SM 36:1	0.0191	1.45×10^{-1}	4.89×10^{-1}
SM 36:2	-0.0085	3.24×10^{-1}	4.89×10^{-1}
SM 36:3	-0.0320	3.15×10^{-2}	4.89×10^{-1}
SM 37:2	-0.0332	2.43×10^{-2}	4.89×10^{-1}
SM 38:1	-0.0179	1.20×10^{-1}	4.89×10^{-1}
SM 38:2	-0.0207	9.77×10^{-2}	4.89×10^{-1}
SM 39:1	-0.0226	6.47×10^{-2}	4.89×10^{-1}
SM 41:1	-0.0673	3.58×10^{-4}	$\mathbf{2.00 \times 10^{-2}}$
SM 41:2	-0.0396	7.96×10^{-3}	3.82×10^{-1}
SM 42:1	-0.0362	3.35×10^{-2}	4.89×10^{-1}
LPC 14:0	0.0069	3.28×10^{-1}	4.89×10^{-1}
LPC 15:0	-0.0423	2.45×10^{-3}	1.30×10^{-1}
LPC 16:0	-0.0073	3.10×10^{-1}	4.89×10^{-1}
LPC 16:1	0.0214	7.56×10^{-2}	4.89×10^{-1}
LPC 17:0	-0.0270	2.81×10^{-2}	4.89×10^{-1}
LPC 17:1	-0.0134	1.86×10^{-1}	4.89×10^{-1}
LPC 18:0	0.0134	1.95×10^{-1}	4.89×10^{-1}
LPC 18:1	-0.0137	1.72×10^{-1}	4.89×10^{-1}
LPC 18:2	-0.0237	6.78×10^{-2}	4.89×10^{-1}
LPC 18:3	0.0214	7.85×10^{-2}	4.89×10^{-1}
LPC 20:0	-0.0084	3.06×10^{-1}	4.89×10^{-1}
LPC 20:1	-0.0042	3.98×10^{-1}	4.89×10^{-1}
LPC 20:2	-0.0035	4.04×10^{-1}	4.89×10^{-1}
LPC 20:3	-0.0044	3.88×10^{-1}	4.89×10^{-1}

TABLE 2. (continued).

Lipid species	β	Nominal p	FDR-p
LPC 20:4	0.0079	3.05×10^{-1}	4.89×10^{-1}
LPC 20:5	0.0198	9.77×10^{-2}	4.89×10^{-1}
LPC 22:0	-0.0083	2.98×10^{-1}	4.89×10^{-1}
LPC 22:1	0.0106	2.48×10^{-1}	4.89×10^{-1}
LPC 22:6	-0.0048	3.68×10^{-1}	4.89×10^{-1}
LPC 24:0	-0.0101	2.68×10^{-1}	4.89×10^{-1}
LPC 26:0	-0.0004	4.89×10^{-1}	4.89×10^{-1}
PC(P-32:0)	0.0237	6.05×10^{-2}	4.89×10^{-1}
PC(P-32:1)	0.0220	7.65×10^{-2}	4.89×10^{-1}
PC(P-34:1)	-0.0115	2.49×10^{-1}	4.89×10^{-1}
PC(P-34:2)	-0.0426	2.91×10^{-3}	1.51×10^{-1}
PC(P-36:2)	-0.0242	5.56×10^{-2}	4.89×10^{-1}
PC(P-36:5)	-0.0026	4.31×10^{-1}	4.89×10^{-1}
PC(P-38:5)	-0.0052	3.66×10^{-1}	4.89×10^{-1}
PC(P-40:5)	0.0105	2.32×10^{-1}	4.89×10^{-1}

[a]All models are adjusted for age, age^2, sex, age x sex, age^2 x sex, use of lipid lowering medications, body mass index, HOMA-IR, total serum cholesterol, serum triglycerides and serum high density lipoproteins. FDR-p, Corrected significance value using Benjamini and Hochberg's method of controlling false discovery rate.

non-diabetics who progressed to diabetes during follow-up also showed higher dhCer 18:0 levels at baseline than non-progressors ($P = 2.2 \times 10^{-8}$). This predictive relationship was maintained ($P = 1.2 \times 10^{-4}$) even when baseline fasting glucose and insulin levels were taken into account, indicating that this lipid component appears to be an independent predictor of diabetes risk. Considering these observations in totality, our results are novel, important and informative in support of the use of WC as a screening tool for T2D/IR risk in Mexican Americans.

The exact mechanistic basis of the observed association between dihydroceramides and waist circumference is currently unknown. It is also unclear whether the plasma dihydroceramide concentrations are better representative of the visceral fat or the subcutaneous fat— a point of debate in the value of WC as a predictor of T2D (18). It has been long recognized that dihydroceramides are the biosynthetic precursors of ceramides—a lipid class that partakes in the release of cytochrome C from mitochondria (36). Moreover, there is evidence (37) to suggest that de novo accumulation of ceramides can be detrimental to pancreatic beta cells and can thus initiate the pathogenesis of T2D. Ceramides are also known to participate in the DES1 pathway and thereby modify the risk of T2D/IR. Conceivably, the plasma concentrations of dihydroceramides may be indicative of raised intracellular levels of ceramides especially since the DES2 pathway is involved in the conversion of dihydroceramides to ceramides (38), but data in this regard are currently lacking. It is also interesting to note from our results that plasma levels of ceramides and dihydroceramides have differential strengths of association with WC and it is unclear which of these classes might more faithfully represent pathways that implicate intracellular ceramide levels. In the absence of direct evidence however, the potential involvement of the DES1/DES2 should be considered only conjectural at this

TABLE 3 Bivariate trait analyses[a] of lipid species with WC

Lipid species	ρ_g	P_g	ρ_e	P_e
dhCer 18:0	0.1972	0.2228	0.1053	0.0001
dhCer 20:0	0.2779	0.0889	0.0801	0.0001
dhCer 22:0	0.4221	0.0038	−0.0297	0.0056
dhCer 24:1	0.4557	0.0017	0.0338	<0.0001
SM 31:1	−0.2193	0.0829	−0.0640	0.0008
SM 41:1	−0.2660	0.0727	−0.0423	0.0022

[a]All models are adjusted for age, age², sex, age x sex, age² x sex, use of lipid lowering medications, body mass index, HOMA-IR, total serum cholesterol, serum triglycerides and serum high density lipoproteins.
ρ_g, genetic correlation coefficient; P_g, significance value for genetic correlation coefficient; ρ_e, environmental correlation coefficient; P_e, significance value for environmental correlation coefficient.

point in time. Future studies therefore need to identify the genetic and biological bases for the strong association of dihydroceramides with waist circumference observed in this study.

An interesting observation made in this study relates to the inverse association of two sphingomyelin species (SM 31:1 and SM 41:1) with waist circumference. This is somewhat surprising considering the general understanding that sphingomyelins are associated with increased risk of obesity, atherosclerosis and metabolic syndrome. However, Cantrell Stanford et al. (39) have recently shown a potentially beneficial role of sphingolipids in the plasma membrane of pancreatic beta cells such that higher levels of these sphingolipids can facilitate glucose-stimulated insulin secretion and thereby improve glycemic control. Whether plasma levels of sphingomyelins faithfully capture the sphingolipid levels in beta cells is currently not known and needs to be investigated in future studies.

An important methodological implication of our results relates to the trade-off between simplicity and accuracy in the reporting of lipidomic studies. It is intuitively appealing to summarize and present the results at the level of lipid classes. However, results shown in Table 1 clearly demonstrate that such a class-based synopsis may be an oversimplification of the underlying spectrum of species-specific associations. The within-class heterogeneity of associations should not be neglected. These results also concur with earlier observations that some (but not all) TGs are more significantly associated with HOMA-IR. For example, Kotrenon et al. (27) found that only TG 16:0 16:0 18:1 was a significant predictor of HOMA-IR. Together, these results indicate that the enhanced resolution offered by lipidomic studies can be used advantageously to characterize lipidomic associations with various disease states.

In addition to the fact that we did not have information on visceral and subcutaneous lipid profiles, some other limitations of the study also need to be considered. First, ethnicity, age and sex are known to confound the association of WC with the risk of T2D and insulin resistance (18). Whether these confounders are also operative in the context of the association of WC with the plasma lipid profile remains unknown. In our analytical protocol we included age, sex, and interactions thereof as covariates in all the polygenic models. Therefore, our results are unlikely to be affected by the age and sex composition of this cohort. However, this study was conducted only in Mexican-Americans and therefore cannot be generalized to other

ethnic populations. Second, WC is a heritable trait (20,21,40) and therefore beckons a need for appropriate statistical models in the family settings. Our use of polygenic models isolates the heritable and modifiable components of WC. Our results are thus unlikely to be affected by the heritability of WC.

On the other hand, our study has several strengths. To our knowledge, this is the first study providing associative evidence for the relationship between WC and dihydroceramides. Second, large-scale plasma lipid studies with epidemiologic overtones are still in the stage of infancy. To that end we believe that our observations are both novel and important. Lastly, our results proffer additional and indirect biological credence to the established role of WC in the pathogenesis of T2D and IR in high prevalence scenarios. O

Acknowledgments

References

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640-1645.

2. Appel SJ, Harrell JS, Davenport ML. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults. *J Am Acad Nurse Pract* 2005;17:535-541.

3. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. *Nutr Res Rev* 2010;23:247-269.

4. Mamtani MR, Kulkarni HR. Predictive performance of anthropometric indexes of central obesity for the risk of type 2 diabetes. *Arch Med Res* 2005;36:581-589.

5. Li JK, Ng MC, So WY, et al. Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2 diabetes mellitus. *Diabetes Metab Res Rev* 2006;22:46-52.

6. Urrutia-Rojas X, Menchaca J, Wadley W, et al. Cardiovascular risk factors in Mexican-American children at risk for type 2 diabetes mellitus (T2DM). *J Adolesc Health Off Publ Soc Adolesc Med* 2004;34:290-299.

7. Ness-Abramof R, Apovian CM. Waist circumference measurement in clinical practice. *Nutr Clin Pract Off Publ Am Soc Parent Enteral Nutr* 2008;23:397-404.

8. Schulze MB, Thorand B, Fritsche A, et al. Body adiposity index, body fat content and incidence of type 2 diabetes. *Diabetologia* 2012;55:1660-1667.

9. Stevens J, Couper D, Pankow J, et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. *Obes Res* 2001;9:696-705.

10. Warren TY, Wilcox S, Dowda M, et al. Independent association of waist circumference with hypertension and diabetes in African American women, South Carolina, 2007-2009. *Prevent Chronic Dis* 2012;9:E105.

11. Wei M, Gaskill SP, Haffner SM, et al. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans—a 7-year prospective study. *Obes Res* 1997;5:16-23.

12. Gao JB, Cheng JL, Ding HP, et al. The disease characteristics and risk factors of type 2 diabetes mellitus in pedigrees. *Zhong Nei Ke Za Zhi (Chin J Inter Med)* 2011;50:474-477.

13. Camhi SM, Bray GA, Bouchard C, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. *Obesity (Silver Spring)* 2011;19:402-408.

14. Sekikawa A, Kadowaki T, Curb JD, et al. Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in Japanese, white, and Japanese American middle-aged men. *J Interferon Cytokine Res* 2010;30:541-548.

15. Hayashi T, Boyko EJ, McNeely MJ, et al. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. *Diabetes* 2008;57:1269-1275.

16. Carroll JF, Chiapa AL, Rodriquez M, et al. Visceral fat, waist circumference, and BMI: impact of race/ethnicity. *Obesity (Silver Spring)* 2008;16:600-607.

17. Sharp DB, Santos LA, Cruz ML. Fatty liver in adolescents on the U.S.-Mexico border. *J Am Acad Nurse Pract* 2009;21:225-230.

18. Vazquez G, Duval S, Jacobs DR, Jr, et al. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. *Epidemiol Rev* 2007;29:115-128.

19. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among US adults. *Obesity Res* 2003;11:1223-1231.

20. Bastarrachea RA, Kent J Jr, Comuzzie AG. Study of the genetic component of cardiovascular risk phenotypes in a Mexican population. *Med Clin* 2007;129:11-13.

21. Voruganti VS, Lopez-Alvarenga JC, Nath SD, et al. Genetics of variation in HOMA-IR and cardiovascular risk factors in Mexican-Americans. *J Mol Med (Berl)* 2008;86:303-311.

22. Pietilainen KH, Sysi-Aho M, Rissanen A, et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects—a monozygotic twin study. *PloS one* 2007;2:e218.

23. Stevens T, Berk MP, Lopez R, et al. Lipidomic profiling of serum and pancreatic fluid in chronic pancreatitis. *Pancreas* 2012;41:518-522.

24. Del Boccio P, Pieragostino D, Di Ioia M, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. *J Proteom* 2011; 74:2826-2836.

25. Lankinen M, Schwab U, Gopalacharyulu PV, et al. Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. *Nutr Metab Cardiovasc Dis NMCD* 2010;20:249-257.

26. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. *Obesity (Silver Spring)* 2010;18:937-944.

27. Kotronen A, Velagapudi VR, Yetukuri L, et al. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. *Diabetologia* 2009;52:684-690.

28. Zhao C, Mao J, Ai J, et al. Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus. *BMC Med Genom* 2013;6 (Suppl 1):S12.

29. MacCluer JW, Stern MP, Almasy L, et al. Genetics of atherosclerosis risk factors in Mexican Americans. *Nutr Rev* 1999;57:S59-S65.

30. Meikle PJ, Wong G, Tsorotes D, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. *Arteriosclerosis Thromb Vascular Biol* 2011;31: 2723-2732.

31. Murphy RC, James PF, McAnoy AM, et al. Detection of the abundance of diacylglycerol and triacylglycerol molecular species in cells using neutral loss mass spectrometry. *Anal Biochem* 2007;366:59-70.

32. Smyth I, Hacking DF, Hilton AA, et al. A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis. *PLoS Genet* 2008;4: e1000192.

33. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet* 1998;62:1198-1211.

34. Qu HQ, Li Q, Rentfro AR, et al. The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. *PloS One* 2011;6: e21041.

35. Curran JE, Weir JM, Bellis C, et al. Lipidomic profiles as endophenotypes for predicting diabetes progression in Mexican Americans. *Eur J Clin Nutr* 2011;19 Suppl 2:36-37.

36. Samad F, Badeanlou L, Shah C, et al. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. *Adv Exp Med Biol* 2011;721:67-86.

37. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. *Endocrinology* 2003;144:5159-5165.

38. Enomoto A, Omae F, Miyazaki M, et al. Dihydroceramide:sphinganine C-4-hydroxylation requires Des2 hydroxylase and the membrane form of cytochrome b5. *Biochem J* 2006;397:289-295.

39. Cantrell Stanford J, Morris AJ, Sunkara M, et al. Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells. *J Biol Chem* 2012;287:13457-13464.

40. Bayoumi RA, Al-Yahyaee SA, Albarwani SA, et al. Heritability of determinants of the metabolic syndrome among healthy Arabs of the Oman family study. *Obesity (Silver Spring)* 2007;15:551-556.